2017-03-07,Revance Completes Enrollment In Phase 3 Pivotal Trials Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines
2017-03-03,Revance Announces BELMONT Phase 2 Clinical Data To Be Presented At The 2017 American Academy Of Dermatology (AAD) Annual Meeting
2017-02-27,Revance Releases Fourth Quarter And Full Year 2016 Results
2017-02-22,Revance To Participate In Upcoming Investor Conferences
2017-02-16,Revance Therapeutics To Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017
2017-01-26,BELMONT Phase 2 Clinical Data To Be Presented At IMCAS World Congress 2017
2017-01-18,Revance Presents Clinical Data For RT002 Injectable At TOXINS 2017
2017-01-05,Revance Provides Clinical Milestones And Financial Outlook For 2017
2016-12-12,Revance Announces Positive 24-Week Duration Of Effect In Interim Results From Phase 2 Cervical Dystonia Trial
2016-12-07,Revance Announces Initiation Of Subject Dosing In The SAKURA Phase 3 Clinical Program Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines
2016-11-17,Revance To Participate In The 28th Annual Piper Jaffray Healthcare Conference
2016-11-07,Revance To Participate In The Jefferies 2016 London Healthcare Conference
2016-11-03,Revance Releases Third Quarter 2016 Results
2016-11-03,Revance Announces Initiation Of Phase 2 Trial Of RT002 Injectable To Treat Plantar Fasciitis
2016-10-24,Revance Therapeutics To Release Third Quarter 2016 Financial Results Thursday, November 3, 2016
2016-10-04,Commit To Buy Revance Therapeutics At $10, Earn 10.1% Annualized Using Options
2016-08-30,Revance To Participate In The 2016 Wells Fargo Securities Healthcare Conference
2016-08-04,Revance Releases Second Quarter 2016 Results
2016-07-21,Revance Therapeutics To Release Second Quarter 2016 Financial Results Thursday, August 4, 2016
2016-07-15,These 5 Stocks Are Primed for Breakouts
2016-07-14,Revance Announces Completion Of Pre-Phase 3 Meeting With FDA For RT002 Injectable To Treat Glabellar Lines
2016-07-13,Short Interest In Revance Therapeutics Makes 16.2% Move
2016-07-05,Commit To Buy Revance Therapeutics At $10, Earn 15.2% Annualized Using Options
2016-07-05,Revance Appoints Industry Leader Julian S. Gangolli To Its Board Of Directors
2016-06-14,Revance Therapeutics Becomes Oversold (RVNC)
2016-06-14,Revance Therapeutics (RVNC) Stock Plunging on Drug Results
2016-06-13,Revance Reports Results For RT001 Topical Phase 3 Trial For Lateral Canthal Lines
2016-06-02,Revance Expands Botulinum Toxin Assets By Acquiring Intellectual Property (IP) Portfolio
2016-05-31,Revance To Participate In Upcoming Investor Conferences
2016-05-09,Revance Releases First Quarter 2016 Results
2016-04-25,Revance Therapeutics To Release First Quarter 2016 Financial Results Monday, May 9, 2016
2016-04-19,'Mad Money' Lightning Round: Ciena Is Dead
2016-04-18,Jim Cramer's 'Mad Money' Recap: Here Are Today's Top 10 Winning Stocks
2016-04-10,Allergan Could Buy These Drug Companies Now That the Pfizer Merger Is Scuttled
2016-04-05,Commit To Buy Revance Therapeutics At $17.50, Earn 51.6% Annualized Using Options
2016-03-14,Revance Therapeutics Expands Leadership Team, Appoints Roman G. Rubio, MD, MBA, As Senior Vice President Of Clinical Development
2016-03-05,Revance Announces Late-Breaking Podium Presentation Of Positive 6-Month Duration Results For BELMONT Phase 2 Active Comparator Study Of Injectable RT002 At The 74th Annual Meeting Of The American Academy Of Dermatology
2016-03-02,Revance Releases Fourth Quarter And Full Year 2015 Results
2016-02-29,5 Earnings Stocks Everyone Else Hates -- but You Should Love
2016-02-23,Revance To Participate In Upcoming Investor Conferences
2016-02-18,Oversold Conditions For Revance Therapeutics
2016-02-17,Revance Therapeutics To Release Fourth Quarter And Full Year 2015 Financial Results Wednesday, March 2, 2016
2016-01-07,Revance Specifies 2016 Clinical Program Milestones
2016-01-07,Revance Therapeutics Becomes Oversold (RVNC)
2016-01-07,Revance Therapeutics (RVNC) Highlighted As Weak On High Volume
2016-01-05,Commit To Buy Revance Therapeutics At $22.50, Earn 22% Annualized Using Options
2015-12-24,Revance Therapeutics (RVNC) Stock: Weak On High Volume Today
2015-12-23,Revance Announces Positive Phase 2 Results For RT001 Botulinum Toxin Type A Topical Gel To Treat Axillary Hyperhidrosis
2015-12-14,Revance Appoints Abhay Joshi, PhD, As Chief Operating Officer
2015-11-24,Interesting RVNC Put And Call Options For July 2016
2015-11-23,Revance Therapeutics (RVNC) Strong On High Relative Volume Today
2015-11-20,Revance Therapeutics (RVNC) Weak On High Volume Today
2015-11-19,Revance Therapeutics To Present In The 27th Annual Piper Jaffray Healthcare Conference
2015-11-13,'Mad Money' Lightning Round: Forget Revance, I Want Allergan
2015-11-12,Jim Cramer's 'Mad Money' Recap: There's Negative, and There's Too Negative
2015-11-11,New Lifetime High Reached By Revance Therapeutics (RVNC)
2015-11-09,Revance Therapeutics Releases Third Quarter 2015 Results
2015-11-09,Revance Therapeutics Announces Closing Of Public Offering Of Common Stock
2015-11-04,Revance Therapeutics To Present At Credit Suisse 24th Annual Healthcare Conference
2015-11-04,Revance Therapeutics To Release Third Quarter 2015 Financial Results Monday, November 9, 2015
2015-11-04,Revance Therapeutics (RVNC) Is Today's Pre-Market Mover With Heavy Volume Stock
2015-11-04,Revance Therapeutics Announces Pricing Of Public Offering Of Common Stock
2015-11-02,Revance Therapeutics Announces Proposed Public Offering Of Common Stock
2015-10-30,Trade-Ideas: Revance Therapeutics (RVNC) Is Today's "Perilous Reversal" Stock
2015-10-29,Jim Cramer -- Revance's Drug Results Are Better Than Allergan's Botox
2015-10-29,Revance Reports Positive 6-Month Duration In BELMONT Study
2015-10-21,Ratings Changes Today
2015-09-29,Revance Therapeutics Initiates Phase 2 Clinical Study Of Its Unique Botulinum Toxin Type A For Injection To Treat Cervical Dystonia
2015-09-28,Revance Therapeutics Initiates Phase 3 Clinical Trial Of Botulinum Toxin Type A Topical Gel To Treat Lateral Canthal Lines
2015-09-09,Revance Therapeutics Initiates Phase 2 Clinical Trial Of Botulinum Toxin Type A Topical Gel To Treat Axillary Hyperhidrosis
2015-08-18,Commit To Purchase Revance Therapeutics At $30, Earn 47.8% Annualized Using Options
2015-08-06,Revance Therapeutics Releases Second Quarter 2015 Results
2015-07-23,Revance Therapeutics To Release Second Quarter 2015 Financial Results Thursday, August 6, 2015
2015-07-02,Revance Therapeutics Announces Change In Role Of Jacob Waugh, M.D.
2015-06-03,Revance Therapeutics (RVNC) Is Strong On High Volume Today
2015-06-03,Revance Therapeutics To Initiate Two Key Trials For RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate
2015-05-21,Revance To Participate In Upcoming Investor Conferences
2015-05-19,First Week Of RVNC January 2016 Options Trading
2015-05-15,Trade-Ideas: Revance Therapeutics (RVNC) Is Today's Strong On High Relative Volume Stock
2015-05-13,Revance Therapeutics Releases First Quarter 2015 Financial Results
2015-05-11,4 Big-Volume Stocks to Trade for Breakouts
2015-04-29,Revance Therapeutics To Release First Quarter 2015 Financial Results Wednesday, May 13, 2015
2015-04-10,Ratings Changes Today
2015-03-16,4 Stocks Spiking on Big Volume: Arista Networks and More
2015-03-09,Ratings Changes Today
2015-03-02,Revance Therapeutics Releases Fourth Quarter And Full Year 2014 Financial Results And Reiterates 2015 Outlook
2015-02-26,Revance Appoints Dr. Philip Vickers To Its Board Of Directors
2015-02-17,Revance Therapeutics, Inc. Announces Participation In Cowen 35th Annual Health Care Conference
2015-02-12,Revance Therapeutics To Release Fourth Quarter And Full Year 2014 Financial Results And Host Conference Call On Monday, March 2, 2015
2015-01-23,Commit To Purchase Revance Therapeutics At $15, Earn 13.2% Annualized Using Options
2015-01-12,Revance Therapeutics Defines Clinical Program Milestones And Provides Financial Guidance For 2015
2015-01-08,Revance Therapeutics Announces Publication Of Positive Results From RT002 Phase 1/2 Study
2015-01-05,Revance Therapeutics Announces Initiation Of BELMONT Phase 2 Active Comparator Trial Of Injectable RT002
2014-12-18,Revance Therapeutics Added To NASDAQ Biotechnology Index
2014-11-20,Revance Therapeutics, Inc. Announces Participation In 26th Annual Piper Jaffray Healthcare Conference
2014-11-12,Revance Therapeutics Releases Third Quarter 2014 Results
2014-11-12,5 Earnings Short-Squeeze Plays: Weibo, Kohl's and More
2014-11-04,Revance Therapeutics, Inc. Announces Participation In Credit Suisse 2014 Healthcare Conference
2014-10-29,Revance Therapeutics To Release Third Quarter 2014 Financial Results And Host Conference Call On Wednesday, November 12, 2014
2014-10-01,Revance Therapeutics Provides Update On RT001 Clinical Program For The Lead Indication For Crow's Feet Lines
2014-09-22,Revance Therapeutics Announces The Appointment Of Azita Nejad As Vice President Of Quality
2014-09-19,Revance Therapeutics Becomes Oversold (RVNC)
2014-09-02,Revance Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2014-08-12,Revance Therapeutics Releases Second Quarter 2014 Financial Results
2014-08-12,Revance Therapeutics Appoints Industry Veteran Arthur P. Bertolino, M.D., Ph.D., M.B.A. As Chief Medical Officer
2014-08-06,RSI Alert: Revance Therapeutics (RVNC) Now Oversold
2014-07-29,Revance Therapeutics To Release Second Quarter 2014 Financial Results And Host Conference Call On Tuesday, August 12, 2014
,
,
